Clopidogrel variability: role of plasma protein binding alterations
British Journal of Clinical Pharmacology2012Vol. 75(6), pp. 1468–1477
Citations Over Time
Abstract
The above in vivo data suggest that the inactive metabolite displaces the active metabolite from binding sites. Thus, the inactive metabolite might increase the free concentration of the active metabolite leading to enhanced inhibition of platelet aggregation. The plasma protein binding mechanism would offer an additional therapeutic strategy to optimize clopidogrel pharmacotherapy.
Related Papers
- → Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel(2000)645 cited
- → Antiplatelet Activity of Clopidogrel in Coronary Artery Bypass Graft Surgery Patients(1999)21 cited
- → Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: Evidence from a meta-regression(2007)17 cited
- Increased mortality after coronary stenting in patients treated with clopidogrel without loading dose. Evidence from a meta-analysis.(2004)
- Effect of clopidogrel on platelet function in patients with unstable angina pectoris(2003)